{"ticker": {"uuid": "6e8f9931-6fff-42b4-bd42-3e6f93676ad7", "symbol": "DYN", "name": "Dyne Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Dyne Therapeutics (DYN) Inspires Confidence With Its Force Platform", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPZGtRRWxIWE81Yk1XUE9aUThSaDJpNmhGc2tWWmNUQ3FWYkhnU09Db2xzUUhpWkF0cVJkUm5IeVcwbmp2TUJLZVpJbXNqSC0wNG9WaDg0dEV3ajg4Z1p2dkFSWXE1TW5NUnZEY21YbDB4aDVvOEZHU2xWdGIzTmJycmJRSlp1NTFKeUNRUUFJcnEyWlNzUW1sYzA3OXRFU3JFVUlhaw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:50+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dyne Therapeutics(DYN.US) Director Sells US$17.86 Million in Common Stock", "summary": "A director at Dyne Therapeutics (DYN.US) sold common stock totaling US$17.86 million. This transaction indicates a significant insider sale at the company.", "url": "https://www.moomoo.com/news/post/72670989/dyne-therapeutics-dynus-director-sells-us-17-86-million-in", "source_name": "Moomoo", "published_at": "2026-07-09T02:11:33", "published_display": "09 Jul 2026 02:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics (DYN) director-linked Atlas funds sell 777K shares under 10b5-1 plan", "summary": "Venture funds affiliated with Dyne Therapeutics (DYN) director Jason P. Rhodes sold a combined total of 777,451 shares of common stock on July 6-7, 2026, under a Rule 10b5-1 trading plan. The sales occurred at weighted-average prices between $22.79 and $23.62 per share. Despite t", "url": "https://www.stocktitan.net/sec-filings/DYN/form-4-dyne-therapeutics-inc-insider-trading-activity-e39a3b8539b5.html", "source_name": "Stock Titan", "published_at": "2026-07-09T02:11:33", "published_display": "09 Jul 2026 02:11", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne therapeutics director Jason Rhodes sells $17.86 million in stock", "summary": "Dyne Therapeutics director Jason P. Rhodes sold approximately $17.86 million worth of company stock through various Atlas Venture funds on July 6 and 7, 2026. These sales, executed via a Rule 10b5-1 trading plan, occurred while the stock was trading near its 52-week high after a ", "url": "https://www.investing.com/news/insider-trading-news/dyne-therapeutics-director-jason-rhodes-sells-1786-million-in-stock-93CH-4782688", "source_name": "Investing.com", "published_at": "2026-07-09T00:11:33", "published_display": "09 Jul 2026 00:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Dyne Therapeutics Inc For: 8 July By Investing.com", "summary": "This article announces that Dyne Therapeutics Inc. filed a Form 4 for July 8th. The filing is a standard disclosure related to insider trading, though no specific details of the transaction are provided in this brief announcement. The article is very short and predominantly featu", "url": "https://ng.investing.com/news/stock-market-news/form-4-dyne-therapeuticsinc-for-8-july-93CH-2591972", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T22:44:00", "published_display": "08 Jul 2026 22:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Dyne Therapeutics, Inc. SEC Filing", "summary": "This article reports on Dyne Therapeutics, Inc.'s SEC Form 144 filing, which indicates a proposed sale of securities. The filing details include the type of securities, the number of shares to be sold, their aggregate market value, and the acquisition transaction details. The com", "url": "https://www.stocktitan.net/sec-filings/DYN/144-dyne-therapeutics-inc-sec-filing-3eb3b67f606e.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:09:33", "published_display": "07 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(DYN) Movement Within Algorithmic Entry Frameworks", "summary": "This article analyzes Dyne Therapeutics Inc. (NYSE: DYN) based on algorithmic entry frameworks, highlighting strong sentiment across all time horizons. It provides three distinct trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with specific entry, target,", "url": "https://news.stocktradersdaily.com/news_release/52/DYN_Movement_Within_Algorithmic_Entry_Frameworks_070626114002_1783395602.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T23:46:28", "published_display": "06 Jul 2026 23:46", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Barry Greene\u2019s Board Role Shape Dyne Therapeutics\u2019 (DYN) Path From Platform to Products?", "summary": "Dyne Therapeutics has appointed biopharma veteran Barry E. Greene to its Board of Directors. Greene's extensive experience in commercializing complex therapies for rare diseases could bolster investor confidence in Dyne's ability to translate its FORCE platform programs, like z-r", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/will-barry-greenes-board-role-shape-dyne-therapeutics-dyn-pa", "source_name": "Simply Wall Street", "published_at": "2026-07-05T13:46:28", "published_display": "05 Jul 2026 13:46", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Inc (DYN) Stock Price | Analyst Target 40.13 & Strong Buy Consensus", "summary": "Analysts have set a strong buy consensus and a price target of $40.13 for Dyne Therapeutics Inc (DYN). The stock is currently trading at $23.07, reflecting an increase of 5.87% in the last 24 hours. Dyne Therapeutics, a biotechnology company, focuses on developing therapies for s", "url": "https://www.etoro.com/markets/dyn", "source_name": "eToro", "published_at": "2026-07-04T13:12:00", "published_display": "04 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?", "summary": "This article compares Dyne Therapeutics and Recursion Pharmaceuticals, two development-stage biopharma companies, to determine which is a better investment in 2026. Dyne focuses on targeted therapies for neuromuscular diseases and is closer to market entry with its first product,", "url": "https://www.fool.com/coverage/better-buy/2026/07/04/dyne-therapeutics-vs-recursion-pharmaceuticals-which-development-stage-pharma-stock-is-a-better-buy-in-2026/", "source_name": "The Motley Fool", "published_at": "2026-07-04T09:21:00", "published_display": "04 Jul 2026 09:21", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Dyne Therapeutics, Inc. \u2013 NASDAQ:DYN", "summary": "This article displays the \"Price to book forward\" metric for Dyne Therapeutics, Inc. (NASDAQ: DYN) on TradingView. It provides a quick financial overview for the company, accessible through the platform's various financial analysis tools. The page highlights that the market is cu", "url": "https://www.tradingview.com/symbols/NASDAQ-DYN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T05:09:52", "published_display": "03 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/0906c3db-cb84-35f1-9eae-46945db82f28/dyne-therapeutics-vs.-vertex.html", "source_name": "Motley Fool", "published_at": "2026-07-01T15:58:42+00:00", "published_display": "01 Jul 2026 15:58", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne therapeutics director Jason Rhodes sells $10.7m in stock", "summary": "Jason P Rhodes, a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), sold over 504,000 shares of the company's common stock for approximately $10.7 million across two transactions in late June 2026, executed via a Rule 10b5-1 trading plan. Despite the sale, the stock has shown a s", "url": "https://www.investing.com/news/insider-trading-news/dyne-therapeutics-director-jason-rhodes-sells-107m-in-stock-93CH-4769216", "source_name": "Investing.com", "published_at": "2026-07-01T12:39:22", "published_display": "01 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Dyne Therapeutics Inc For: 30 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Dyne Therapeutics Inc. for the period ending June 30. It includes the company's stock symbol DYN, which saw a 4.47% increase, and is dated June 30, 2026, at 07:14 p.m.", "url": "https://ca.investing.com/news/stock-market-news/form-4-dyne-therapeuticsinc-for-30-june-93CH-4715028", "source_name": "Investing.com Canada", "published_at": "2026-07-01T07:10:23", "published_display": "01 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atlas funds linked to Dyne (DYN) director sell 504,695 shares", "summary": "Funds associated with Dyne Therapeutics director Jason P. Rhodes sold 504,695 shares of common stock in open-market transactions on June 26 and June 29, 2026. The sales were executed through Atlas Venture funds at weighted-average prices between $21.14 and $21.28, under a pre-est", "url": "https://www.stocktitan.net/sec-filings/DYN/form-4-dyne-therapeutics-inc-insider-trading-activity-4b9746135296.html", "source_name": "Stock Titan", "published_at": "2026-06-30T23:10:23", "published_display": "30 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma", "summary": "DelveInsight's report highlights that over 20 companies are actively developing more than 22 Myotonic Dystrophy therapies, covering various clinical development stages from pre-clinical to marketed phases. Key emerging therapies include EF-210, ARO-DM1, VX-670, PGN-EDODM1, and DY", "url": "https://www.barchart.com/story/news/3046770/myotonic-dystrophy-pipeline-2026-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-dyne-therapeutics-avidity-biosciences-harmony-biosciences-amo-pharma-lupin-amo-pharma", "source_name": "Barchart.com", "published_at": "2026-06-30T08:09:20", "published_display": "30 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Dyne Therapeutics, Inc. (DYN) on June 29, 2026. The filing indicates a proposed sale of securities, specifically 40,702 shares of common stock acquired via private placement in 2020 by the issuer, with Merrill Lynch as the broker. ", "url": "https://www.stocktitan.net/sec-filings/DYN/144-dyne-therapeutics-inc-sec-filing-4ff0e19967a9.html", "source_name": "Stock Titan", "published_at": "2026-06-30T00:40:24", "published_display": "30 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne therapeutics director Jason P Rhodes sells $5.65m in stock", "summary": "Jason P Rhodes, a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), recently sold 267,760 shares of the company\u2019s common stock for approximately $5.65 million through a Rule 10b5-1 trading plan. These transactions took place between June 23 and June 25, 2026, with prices ranging ", "url": "https://www.investing.com/news/insider-trading-news/dyne-therapeutics-director-jason-p-rhodes-sells-565m-in-stock-93CH-4762791", "source_name": "Investing.com", "published_at": "2026-06-27T10:11:06", "published_display": "27 Jun 2026 10:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Dyne Therapeutics Inc \u2013 BX:DYN", "summary": "This page provides financial data specifically on the \"Price to earnings forward\" for Dyne Therapeutics Inc (BX:DYN). The content indicates the market is closed, with no current trades. It also highlights that financial and reference data are provided by ICE Data Services and Fac", "url": "https://www.tradingview.com/symbols/BX-DYN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:42:09", "published_display": "27 Jun 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Dyne Therapeutics, Inc. \u2013 NASDAQ:DYN", "summary": "This article provides the \"Price to sales forward\" financial metric for Dyne Therapeutics, Inc. (NASDAQ: DYN). It indicates that the period value is available and notes that the market was closed at the time of publication, showing no trades.", "url": "https://www.tradingview.com/symbols/NASDAQ-DYN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:10:00", "published_display": "27 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Dyne Therapeutics Inc \u2013 BX:DYN", "summary": "This article provides forward-looking enterprise value to EBIT data for Dyne Therapeutics Inc (BX:DYN) on TradingView. It appears to be a financial data snippet from a larger platform, showing market status and financial figures.", "url": "https://www.tradingview.com/symbols/BX-DYN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:41:35", "published_display": "27 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics stock initiated at buy by TD Cowen on platform", "summary": "TD Cowen has initiated coverage on Dyne Therapeutics Inc. (NASDAQ:DYN) with a \"buy\" rating, citing the company's FORCE platform and late-stage clinical programs for neuromuscular and CNS diseases. The stock has seen a significant surge of 105% over the past year, reflecting inves", "url": "https://www.investing.com/news/analyst-ratings/dyne-therapeutics-stock-initiated-at-buy-by-td-cowen-on-platform-93CH-4762409", "source_name": "Investing.com", "published_at": "2026-06-26T22:09:45", "published_display": "26 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes", "summary": "Dyne Therapeutics' CFO, Lucera Erick, sold 2,362 shares of common stock at a weighted average price of $20.37 per share. This transaction was conducted to meet tax obligations arising from the vesting and settlement of restricted stock units. Following the sale, Erick retains ben", "url": "https://www.stocktitan.net/sec-filings/DYN/form-4-dyne-therapeutics-inc-insider-trading-activity-04615bd28113.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:16:51", "published_display": "26 Jun 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/bc3aa1d1-041b-3d34-bdaa-67d0e505a2e7/dyne-therapeutics-vs.-viking.html", "source_name": "Motley Fool", "published_at": "2026-06-26T15:25:48+00:00", "published_display": "26 Jun 2026 15:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics(DYN.US) Director Sells US$5.65 Million in Common Stock", "summary": "Dyne Therapeutics (DYN.US) Director, HOLLAND TIMOTHY, sold 160,000 shares of common stock at an average price of $35.33 per share, totaling $5.65 million. This transaction was reported on June 25, 2026.", "url": "https://www.moomoo.com/news/post/72109080/dyne-therapeutics-dynus-director-sells-us-5-65-million-in", "source_name": "Moomoo", "published_at": "2026-06-26T15:41:51", "published_display": "26 Jun 2026 15:41", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/dyne-therapeutics-insider-sold-shares-140254364.html", "source_name": "MT Newswires", "published_at": "2026-06-26T14:02:54+00:00", "published_display": "26 Jun 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com", "summary": "Investing.com reports on a Form 4 filing for Dyne Therapeutics Inc. which occurred on June 26. This brief article primarily serves as an announcement for the regulatory filing related to the company. The specific details of the Form 4 are not provided within the article text.", "url": "https://ca.investing.com/news/stock-market-news/form-4-dyne-therapeuticsinc-for-26-june-93CH-4709474", "source_name": "Investing.com Canada", "published_at": "2026-06-26T12:41:51", "published_display": "26 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares", "summary": "Funds affiliated with Dyne Therapeutics (DYN) director Jason P. Rhodes sold a total of 267,760 shares of common stock between June 23 and June 25, 2026. These open-market sales were executed at weighted average prices around $21 per share, under a pre-arranged Rule 10b5-1 trading", "url": "https://www.stocktitan.net/sec-filings/DYN/form-4-dyne-therapeutics-inc-insider-trading-activity-a2e725c84945.html", "source_name": "Stock Titan", "published_at": "2026-06-26T12:41:51", "published_display": "26 Jun 2026 12:41", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Initiates Dyne Therapeutics at Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/td-cowen-initiates-dyne-therapeutics-100712550.html", "source_name": "MT Newswires", "published_at": "2026-06-26T10:07:12+00:00", "published_display": "26 Jun 2026 10:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Inc Actuals & Estimates (NASDAQ:DYN)", "summary": "This article provides an overview of Dyne Therapeutics Inc. (NASDAQ: DYN), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and recent earnings and revenu", "url": "https://www.tradingview.com/symbols/NASDAQ-DYN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:33", "published_display": "26 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Dyne Therapeutics Inc For: 24 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Dyne Therapeutics Inc. dated June 24. It provides no further details on the filing but includes stock market performance data for Dyne Therapeutics (DYN) and various indices and commodities. The article appears to be ", "url": "https://ca.investing.com/news/stock-market-news/form-4-dyne-therapeuticsinc-for-24-june-93CH-4706459", "source_name": "Investing.com Canada", "published_at": "2026-06-25T23:39:57", "published_display": "25 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics (DYN) Adds Barry Greene And Expands Funding, Is The Stock Still A Bargain?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Insider Sold Shares Worth $5,464,611, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/dyne-therapeutics-insider-sold-shares-203436987.html", "source_name": "MT Newswires", "published_at": "2026-06-24T20:34:36+00:00", "published_display": "24 Jun 2026 20:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Appoints Barry Greene to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyne-therapeutics-appoints-barry-greene-201000320.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T20:10:00+00:00", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barry Greene joins Dyne Therapeutics (DYN) board with new option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPYmtJUHNTb2tkdGpLRFduTUk1T21kUm1ONjRBcTlObHh3VnQyQjlBbW1ZNk1EU0dZNFBnLU5rVUV3Z0F1LUxEWnd5eFhGYkFSUmtMWUROWGdvQm5mWllTM0Q3bmJGVzhvRjdKMG5zX2I3MlNDalVRVXJ5V09UUkd4SFVRVmhxTXRFOFBJbC10aVFzaHY1RXN1ZHZvMC1BUk9FM2p3aTVveXM0NGYzdWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics adds ex-Sage CEO Barry Greene to board", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNTVpzVkI0bXQ2R0NPYnFaOWE4bjBUUTlGUTUzZW1OMmJ4YW5fbzdwQzZPOC1qU1l4cEk4TF9fVEM3ZWNzcVRPbE1rNFJTc1QtOTdrZFJHckVJS1E5NUFiNjdSTEpBWFZpeThLZk1obVlhTGI3V3piS0FPbkFSWTlpckduNHQ5Y3g0TGVWTUlXanFhVjRTNFFHNU9YaEpXRzdacF82d2lOaUo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyne-therapeutics-reports-inducement-grants-200500292.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T20:05:00+00:00", "published_display": "18 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyne-therapeutics-announces-expanded-debt-113000118.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T11:30:00+00:00", "published_display": "17 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics DM1 Trial Reaches Pivotal Stage With ACHIEVE Enrollment", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQZ1JmZzFwdEJicm13c0pIdzlrUkZBXzZuNEJJcktpeW1XcUNod0UwTkZHUFoyak9LVzNiMGlHVV96eHVBOElJMjBYZUF3UzBDcnVJVWUycWxTTk1Zb0dUSTkyQzZFWUw4cFZwT0RrNE8zNWVkeWRTR0JscFdOc0lSWlNwS3pnWGh6dzVMb2NfOW1VTlEwRlRXRzB3aWxYeGVPN2c?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Dyne Therapeutics (DYN) Valuation As Phase 3 FORZETTO Trial Marks Key Development Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQNk1CWTBFbUQ4OUVsWFJ0SVZ0S0Q2elFlSFFienAzUGxMdW5iUWVWM3RVbXpGek5maktDRGJMNFRHZmlIZXo1VEdmQlB6cGF1cDF1d3FYdGdJUWtvV1lYaHBJdUNxUVVBODlpd21OUWpnd3VSVjBvTnVLVkg1MThPWG44cktjR2lBdk5yenRYUl9jTWRQUVpYRWhJVzVkSDFkdmtidkFqa2E?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Dyne Therapeutics (DYN) After A 152% One\u2011Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPZTBZR05ielZ2c1lvQnFtZlZqMW13WUl2M0ROd0RsTVJKN0UzbHFNTVBteVV2cHFmWWpZclJ0RmE4X21RNDlER1JuVkNmaE50S2VCSHpwbjZiUWZ5YXFsMlFXb3QzeUk0Vmw2SjBXQk53aVIzYVdWVGJ6cVU4WWhSZnAwaFU?oc=5", "source_name": "Market source", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DYNE THERAPEUTICS ($DYN) Releases Q4 2025 Earnings | DYN Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQREx0RkVoczFwTnpqNWdCRUp1NUVDeHpLU1dSV3d2TjNRMEtaeXU0OGxfRE1XMm0xWWVOMlZYUVJyMjNVbjJUX0EtdE1YWVhmRGJYU2F3RnQtTXpmcXNiQ3lCTE1lVEZ0OWszYUJJRWlrVmQybFF0MVBWSmNPbmlHVWlyVTM4TE4tb3RpU3FKY0FqeWs?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQb1I1ODRjNXoyNmNxT000RVcwQTRkcGhsNXZ3SzFadGlYdkNuRThkc1dRUmVIUExBM2tqaHVaMUNQY3d3eFk2WFRoWGF6YzlyYXhYYnlhdUloaWlsOFRkQ0pPY1ktMkYxbDdyckV6bWdoZ0w4R1ZkQXpYRVRKRmFHdGpoSUVpM2hXcnBUTFY1Vl9QajA0cFFKR2tpeE1ITnM2a3NQeC1TZ3F6VV9fY083RkJad1FWRTE3TmJwd0t3?oc=5", "source_name": "The Motley Fool", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPUUx5VF80eUpFTGp4Znc3ejRxQ2wtZUNtSmMxN3l3WnhpQWRJWmRhWmItZE53YjBlaUctZVU2ZXZPT3ZYRS1UY1RUTF9TcUVvYk1qZGJwZU9RcUw0alhfcVlXYWlzY21SaXdaak9DVHZUYngtOHkwQlBjY3F6VWhSOEw5RkczaFlmaTFnLXVxeXR5SWowQWl0ZTNTb2xCcGhEM2JrazAyQzNNVlpUMmtjMkEwNmswNDdiYXFLV1lMVjJfVVF3RnZYRElvVzIzd1NFclhpQ1VCbEZqWnQ1a3pzX3FwaGVHQQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-27T15:43:01+00:00", "published_display": "27 Oct 2025 15:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNZGFMMk8wYVU5aExvLS1RZXJXRVZQSzM4bnhnYy00bE9kUE96NWpwa05oMW5BQW5Fb2FHbmhUejlhOWxXNmFMUnd6aDFmeU9yTVQ1QzBXaFpLekpjbG9nUWJOekhTMnJidEl0Y0UtTGtzZXdjREtRNDFEVXREaDdLazlOYWJYdkVDLURNSzhWT0l6YUZZSFV5c1M0dmkwakdUYTB4U2t1dw?oc=5", "source_name": "Investopedia", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPYkdRdnl1ekhjeXZYY0NmY3U0bE5CaWM1d0tnUVNLU2RiYnJfMnBHdElJc082NU8wQ0JnaktNMVNLZTNSTEdQTmREV1ByekJvMV9fdUVuSmx1TERRV0NIZUs2Wkpodno5VTIyNEdIbDFMemFvUHVDeE0xYmJGeC00bGlXcXVYblhLWnI1X2pkUGl1UGpWR3JhUjNOZjg4ZFFNRWc?oc=5", "source_name": "CNBC", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Dyne Therapeutics (DYN) Inspires Confidence With Its Force Platform", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPZGtRRWxIWE81Yk1XUE9aUThSaDJpNmhGc2tWWmNUQ3FWYkhnU09Db2xzUUhpWkF0cVJkUm5IeVcwbmp2TUJLZVpJbXNqSC0wNG9WaDg0dEV3ajg4Z1p2dkFSWXE1TW5NUnZEY21YbDB4aDVvOEZHU2xWdGIzTmJycmJRSlp1NTFKeUNRUUFJcnEyWlNzUW1sYzA3OXRFU3JFVUlhaw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:50+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics(DYN.US) Director Sells US$17.86 Million in Common Stock", "summary": "A director at Dyne Therapeutics (DYN.US) sold common stock totaling US$17.86 million. This transaction indicates a significant insider sale at the company.", "url": "https://www.moomoo.com/news/post/72670989/dyne-therapeutics-dynus-director-sells-us-17-86-million-in", "source_name": "Moomoo", "published_at": "2026-07-09T02:11:33", "published_display": "09 Jul 2026 02:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics (DYN) director-linked Atlas funds sell 777K shares under 10b5-1 plan", "summary": "Venture funds affiliated with Dyne Therapeutics (DYN) director Jason P. Rhodes sold a combined total of 777,451 shares of common stock on July 6-7, 2026, under a Rule 10b5-1 trading plan. The sales occurred at weighted-average prices between $22.79 and $23.62 per share. Despite t", "url": "https://www.stocktitan.net/sec-filings/DYN/form-4-dyne-therapeutics-inc-insider-trading-activity-e39a3b8539b5.html", "source_name": "Stock Titan", "published_at": "2026-07-09T02:11:33", "published_display": "09 Jul 2026 02:11", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne therapeutics director Jason Rhodes sells $17.86 million in stock", "summary": "Dyne Therapeutics director Jason P. Rhodes sold approximately $17.86 million worth of company stock through various Atlas Venture funds on July 6 and 7, 2026. These sales, executed via a Rule 10b5-1 trading plan, occurred while the stock was trading near its 52-week high after a ", "url": "https://www.investing.com/news/insider-trading-news/dyne-therapeutics-director-jason-rhodes-sells-1786-million-in-stock-93CH-4782688", "source_name": "Investing.com", "published_at": "2026-07-09T00:11:33", "published_display": "09 Jul 2026 00:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Dyne Therapeutics Inc For: 8 July By Investing.com", "summary": "This article announces that Dyne Therapeutics Inc. filed a Form 4 for July 8th. The filing is a standard disclosure related to insider trading, though no specific details of the transaction are provided in this brief announcement. The article is very short and predominantly featu", "url": "https://ng.investing.com/news/stock-market-news/form-4-dyne-therapeuticsinc-for-8-july-93CH-2591972", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T22:44:00", "published_display": "08 Jul 2026 22:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Dyne Therapeutics, Inc. SEC Filing", "summary": "This article reports on Dyne Therapeutics, Inc.'s SEC Form 144 filing, which indicates a proposed sale of securities. The filing details include the type of securities, the number of shares to be sold, their aggregate market value, and the acquisition transaction details. The com", "url": "https://www.stocktitan.net/sec-filings/DYN/144-dyne-therapeutics-inc-sec-filing-3eb3b67f606e.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:09:33", "published_display": "07 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(DYN) Movement Within Algorithmic Entry Frameworks", "summary": "This article analyzes Dyne Therapeutics Inc. (NYSE: DYN) based on algorithmic entry frameworks, highlighting strong sentiment across all time horizons. It provides three distinct trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with specific entry, target,", "url": "https://news.stocktradersdaily.com/news_release/52/DYN_Movement_Within_Algorithmic_Entry_Frameworks_070626114002_1783395602.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T23:46:28", "published_display": "06 Jul 2026 23:46", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Barry Greene\u2019s Board Role Shape Dyne Therapeutics\u2019 (DYN) Path From Platform to Products?", "summary": "Dyne Therapeutics has appointed biopharma veteran Barry E. Greene to its Board of Directors. Greene's extensive experience in commercializing complex therapies for rare diseases could bolster investor confidence in Dyne's ability to translate its FORCE platform programs, like z-r", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/will-barry-greenes-board-role-shape-dyne-therapeutics-dyn-pa", "source_name": "Simply Wall Street", "published_at": "2026-07-05T13:46:28", "published_display": "05 Jul 2026 13:46", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Inc (DYN) Stock Price | Analyst Target 40.13 & Strong Buy Consensus", "summary": "Analysts have set a strong buy consensus and a price target of $40.13 for Dyne Therapeutics Inc (DYN). The stock is currently trading at $23.07, reflecting an increase of 5.87% in the last 24 hours. Dyne Therapeutics, a biotechnology company, focuses on developing therapies for s", "url": "https://www.etoro.com/markets/dyn", "source_name": "eToro", "published_at": "2026-07-04T13:12:00", "published_display": "04 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?", "summary": "This article compares Dyne Therapeutics and Recursion Pharmaceuticals, two development-stage biopharma companies, to determine which is a better investment in 2026. Dyne focuses on targeted therapies for neuromuscular diseases and is closer to market entry with its first product,", "url": "https://www.fool.com/coverage/better-buy/2026/07/04/dyne-therapeutics-vs-recursion-pharmaceuticals-which-development-stage-pharma-stock-is-a-better-buy-in-2026/", "source_name": "The Motley Fool", "published_at": "2026-07-04T09:21:00", "published_display": "04 Jul 2026 09:21", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Dyne Therapeutics, Inc. \u2013 NASDAQ:DYN", "summary": "This article displays the \"Price to book forward\" metric for Dyne Therapeutics, Inc. (NASDAQ: DYN) on TradingView. It provides a quick financial overview for the company, accessible through the platform's various financial analysis tools. The page highlights that the market is cu", "url": "https://www.tradingview.com/symbols/NASDAQ-DYN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T05:09:52", "published_display": "03 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/0906c3db-cb84-35f1-9eae-46945db82f28/dyne-therapeutics-vs.-vertex.html", "source_name": "Motley Fool", "published_at": "2026-07-01T15:58:42+00:00", "published_display": "01 Jul 2026 15:58", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne therapeutics director Jason Rhodes sells $10.7m in stock", "summary": "Jason P Rhodes, a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), sold over 504,000 shares of the company's common stock for approximately $10.7 million across two transactions in late June 2026, executed via a Rule 10b5-1 trading plan. Despite the sale, the stock has shown a s", "url": "https://www.investing.com/news/insider-trading-news/dyne-therapeutics-director-jason-rhodes-sells-107m-in-stock-93CH-4769216", "source_name": "Investing.com", "published_at": "2026-07-01T12:39:22", "published_display": "01 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Dyne Therapeutics Inc For: 30 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Dyne Therapeutics Inc. for the period ending June 30. It includes the company's stock symbol DYN, which saw a 4.47% increase, and is dated June 30, 2026, at 07:14 p.m.", "url": "https://ca.investing.com/news/stock-market-news/form-4-dyne-therapeuticsinc-for-30-june-93CH-4715028", "source_name": "Investing.com Canada", "published_at": "2026-07-01T07:10:23", "published_display": "01 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atlas funds linked to Dyne (DYN) director sell 504,695 shares", "summary": "Funds associated with Dyne Therapeutics director Jason P. Rhodes sold 504,695 shares of common stock in open-market transactions on June 26 and June 29, 2026. The sales were executed through Atlas Venture funds at weighted-average prices between $21.14 and $21.28, under a pre-est", "url": "https://www.stocktitan.net/sec-filings/DYN/form-4-dyne-therapeutics-inc-insider-trading-activity-4b9746135296.html", "source_name": "Stock Titan", "published_at": "2026-06-30T23:10:23", "published_display": "30 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma", "summary": "DelveInsight's report highlights that over 20 companies are actively developing more than 22 Myotonic Dystrophy therapies, covering various clinical development stages from pre-clinical to marketed phases. Key emerging therapies include EF-210, ARO-DM1, VX-670, PGN-EDODM1, and DY", "url": "https://www.barchart.com/story/news/3046770/myotonic-dystrophy-pipeline-2026-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-dyne-therapeutics-avidity-biosciences-harmony-biosciences-amo-pharma-lupin-amo-pharma", "source_name": "Barchart.com", "published_at": "2026-06-30T08:09:20", "published_display": "30 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Dyne Therapeutics, Inc. (DYN) on June 29, 2026. The filing indicates a proposed sale of securities, specifically 40,702 shares of common stock acquired via private placement in 2020 by the issuer, with Merrill Lynch as the broker. ", "url": "https://www.stocktitan.net/sec-filings/DYN/144-dyne-therapeutics-inc-sec-filing-4ff0e19967a9.html", "source_name": "Stock Titan", "published_at": "2026-06-30T00:40:24", "published_display": "30 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne therapeutics director Jason P Rhodes sells $5.65m in stock", "summary": "Jason P Rhodes, a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), recently sold 267,760 shares of the company\u2019s common stock for approximately $5.65 million through a Rule 10b5-1 trading plan. These transactions took place between June 23 and June 25, 2026, with prices ranging ", "url": "https://www.investing.com/news/insider-trading-news/dyne-therapeutics-director-jason-p-rhodes-sells-565m-in-stock-93CH-4762791", "source_name": "Investing.com", "published_at": "2026-06-27T10:11:06", "published_display": "27 Jun 2026 10:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Dyne Therapeutics Inc \u2013 BX:DYN", "summary": "This page provides financial data specifically on the \"Price to earnings forward\" for Dyne Therapeutics Inc (BX:DYN). The content indicates the market is closed, with no current trades. It also highlights that financial and reference data are provided by ICE Data Services and Fac", "url": "https://www.tradingview.com/symbols/BX-DYN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:42:09", "published_display": "27 Jun 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Dyne Therapeutics, Inc. \u2013 NASDAQ:DYN", "summary": "This article provides the \"Price to sales forward\" financial metric for Dyne Therapeutics, Inc. (NASDAQ: DYN). It indicates that the period value is available and notes that the market was closed at the time of publication, showing no trades.", "url": "https://www.tradingview.com/symbols/NASDAQ-DYN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:10:00", "published_display": "27 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Dyne Therapeutics Inc \u2013 BX:DYN", "summary": "This article provides forward-looking enterprise value to EBIT data for Dyne Therapeutics Inc (BX:DYN) on TradingView. It appears to be a financial data snippet from a larger platform, showing market status and financial figures.", "url": "https://www.tradingview.com/symbols/BX-DYN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:41:35", "published_display": "27 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics stock initiated at buy by TD Cowen on platform", "summary": "TD Cowen has initiated coverage on Dyne Therapeutics Inc. (NASDAQ:DYN) with a \"buy\" rating, citing the company's FORCE platform and late-stage clinical programs for neuromuscular and CNS diseases. The stock has seen a significant surge of 105% over the past year, reflecting inves", "url": "https://www.investing.com/news/analyst-ratings/dyne-therapeutics-stock-initiated-at-buy-by-td-cowen-on-platform-93CH-4762409", "source_name": "Investing.com", "published_at": "2026-06-26T22:09:45", "published_display": "26 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes", "summary": "Dyne Therapeutics' CFO, Lucera Erick, sold 2,362 shares of common stock at a weighted average price of $20.37 per share. This transaction was conducted to meet tax obligations arising from the vesting and settlement of restricted stock units. Following the sale, Erick retains ben", "url": "https://www.stocktitan.net/sec-filings/DYN/form-4-dyne-therapeutics-inc-insider-trading-activity-04615bd28113.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:16:51", "published_display": "26 Jun 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/bc3aa1d1-041b-3d34-bdaa-67d0e505a2e7/dyne-therapeutics-vs.-viking.html", "source_name": "Motley Fool", "published_at": "2026-06-26T15:25:48+00:00", "published_display": "26 Jun 2026 15:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics(DYN.US) Director Sells US$5.65 Million in Common Stock", "summary": "Dyne Therapeutics (DYN.US) Director, HOLLAND TIMOTHY, sold 160,000 shares of common stock at an average price of $35.33 per share, totaling $5.65 million. This transaction was reported on June 25, 2026.", "url": "https://www.moomoo.com/news/post/72109080/dyne-therapeutics-dynus-director-sells-us-5-65-million-in", "source_name": "Moomoo", "published_at": "2026-06-26T15:41:51", "published_display": "26 Jun 2026 15:41", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/dyne-therapeutics-insider-sold-shares-140254364.html", "source_name": "MT Newswires", "published_at": "2026-06-26T14:02:54+00:00", "published_display": "26 Jun 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com", "summary": "Investing.com reports on a Form 4 filing for Dyne Therapeutics Inc. which occurred on June 26. This brief article primarily serves as an announcement for the regulatory filing related to the company. The specific details of the Form 4 are not provided within the article text.", "url": "https://ca.investing.com/news/stock-market-news/form-4-dyne-therapeuticsinc-for-26-june-93CH-4709474", "source_name": "Investing.com Canada", "published_at": "2026-06-26T12:41:51", "published_display": "26 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares", "summary": "Funds affiliated with Dyne Therapeutics (DYN) director Jason P. Rhodes sold a total of 267,760 shares of common stock between June 23 and June 25, 2026. These open-market sales were executed at weighted average prices around $21 per share, under a pre-arranged Rule 10b5-1 trading", "url": "https://www.stocktitan.net/sec-filings/DYN/form-4-dyne-therapeutics-inc-insider-trading-activity-a2e725c84945.html", "source_name": "Stock Titan", "published_at": "2026-06-26T12:41:51", "published_display": "26 Jun 2026 12:41", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Initiates Dyne Therapeutics at Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/td-cowen-initiates-dyne-therapeutics-100712550.html", "source_name": "MT Newswires", "published_at": "2026-06-26T10:07:12+00:00", "published_display": "26 Jun 2026 10:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Inc Actuals & Estimates (NASDAQ:DYN)", "summary": "This article provides an overview of Dyne Therapeutics Inc. (NASDAQ: DYN), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and recent earnings and revenu", "url": "https://www.tradingview.com/symbols/NASDAQ-DYN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:33", "published_display": "26 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Dyne Therapeutics Inc For: 24 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Dyne Therapeutics Inc. dated June 24. It provides no further details on the filing but includes stock market performance data for Dyne Therapeutics (DYN) and various indices and commodities. The article appears to be ", "url": "https://ca.investing.com/news/stock-market-news/form-4-dyne-therapeuticsinc-for-24-june-93CH-4706459", "source_name": "Investing.com Canada", "published_at": "2026-06-25T23:39:57", "published_display": "25 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics (DYN) Adds Barry Greene And Expands Funding, Is The Stock Still A Bargain?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Insider Sold Shares Worth $5,464,611, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/dyne-therapeutics-insider-sold-shares-203436987.html", "source_name": "MT Newswires", "published_at": "2026-06-24T20:34:36+00:00", "published_display": "24 Jun 2026 20:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Appoints Barry Greene to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyne-therapeutics-appoints-barry-greene-201000320.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T20:10:00+00:00", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barry Greene joins Dyne Therapeutics (DYN) board with new option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPYmtJUHNTb2tkdGpLRFduTUk1T21kUm1ONjRBcTlObHh3VnQyQjlBbW1ZNk1EU0dZNFBnLU5rVUV3Z0F1LUxEWnd5eFhGYkFSUmtMWUROWGdvQm5mWllTM0Q3bmJGVzhvRjdKMG5zX2I3MlNDalVRVXJ5V09UUkd4SFVRVmhxTXRFOFBJbC10aVFzaHY1RXN1ZHZvMC1BUk9FM2p3aTVveXM0NGYzdWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics adds ex-Sage CEO Barry Greene to board", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNTVpzVkI0bXQ2R0NPYnFaOWE4bjBUUTlGUTUzZW1OMmJ4YW5fbzdwQzZPOC1qU1l4cEk4TF9fVEM3ZWNzcVRPbE1rNFJTc1QtOTdrZFJHckVJS1E5NUFiNjdSTEpBWFZpeThLZk1obVlhTGI3V3piS0FPbkFSWTlpckduNHQ5Y3g0TGVWTUlXanFhVjRTNFFHNU9YaEpXRzdacF82d2lOaUo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyne-therapeutics-reports-inducement-grants-200500292.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T20:05:00+00:00", "published_display": "18 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyne-therapeutics-announces-expanded-debt-113000118.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T11:30:00+00:00", "published_display": "17 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics DM1 Trial Reaches Pivotal Stage With ACHIEVE Enrollment", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQZ1JmZzFwdEJicm13c0pIdzlrUkZBXzZuNEJJcktpeW1XcUNod0UwTkZHUFoyak9LVzNiMGlHVV96eHVBOElJMjBYZUF3UzBDcnVJVWUycWxTTk1Zb0dUSTkyQzZFWUw4cFZwT0RrNE8zNWVkeWRTR0JscFdOc0lSWlNwS3pnWGh6dzVMb2NfOW1VTlEwRlRXRzB3aWxYeGVPN2c?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Dyne Therapeutics (DYN) Valuation As Phase 3 FORZETTO Trial Marks Key Development Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQNk1CWTBFbUQ4OUVsWFJ0SVZ0S0Q2elFlSFFienAzUGxMdW5iUWVWM3RVbXpGek5maktDRGJMNFRHZmlIZXo1VEdmQlB6cGF1cDF1d3FYdGdJUWtvV1lYaHBJdUNxUVVBODlpd21OUWpnd3VSVjBvTnVLVkg1MThPWG44cktjR2lBdk5yenRYUl9jTWRQUVpYRWhJVzVkSDFkdmtidkFqa2E?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Dyne Therapeutics (DYN) After A 152% One\u2011Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPZTBZR05ielZ2c1lvQnFtZlZqMW13WUl2M0ROd0RsTVJKN0UzbHFNTVBteVV2cHFmWWpZclJ0RmE4X21RNDlER1JuVkNmaE50S2VCSHpwbjZiUWZ5YXFsMlFXb3QzeUk0Vmw2SjBXQk53aVIzYVdWVGJ6cVU4WWhSZnAwaFU?oc=5", "source_name": "Market source", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DYNE THERAPEUTICS ($DYN) Releases Q4 2025 Earnings | DYN Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQREx0RkVoczFwTnpqNWdCRUp1NUVDeHpLU1dSV3d2TjNRMEtaeXU0OGxfRE1XMm0xWWVOMlZYUVJyMjNVbjJUX0EtdE1YWVhmRGJYU2F3RnQtTXpmcXNiQ3lCTE1lVEZ0OWszYUJJRWlrVmQybFF0MVBWSmNPbmlHVWlyVTM4TE4tb3RpU3FKY0FqeWs?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQb1I1ODRjNXoyNmNxT000RVcwQTRkcGhsNXZ3SzFadGlYdkNuRThkc1dRUmVIUExBM2tqaHVaMUNQY3d3eFk2WFRoWGF6YzlyYXhYYnlhdUloaWlsOFRkQ0pPY1ktMkYxbDdyckV6bWdoZ0w4R1ZkQXpYRVRKRmFHdGpoSUVpM2hXcnBUTFY1Vl9QajA0cFFKR2tpeE1ITnM2a3NQeC1TZ3F6VV9fY083RkJad1FWRTE3TmJwd0t3?oc=5", "source_name": "The Motley Fool", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPUUx5VF80eUpFTGp4Znc3ejRxQ2wtZUNtSmMxN3l3WnhpQWRJWmRhWmItZE53YjBlaUctZVU2ZXZPT3ZYRS1UY1RUTF9TcUVvYk1qZGJwZU9RcUw0alhfcVlXYWlzY21SaXdaak9DVHZUYngtOHkwQlBjY3F6VWhSOEw5RkczaFlmaTFnLXVxeXR5SWowQWl0ZTNTb2xCcGhEM2JrazAyQzNNVlpUMmtjMkEwNmswNDdiYXFLV1lMVjJfVVF3RnZYRElvVzIzd1NFclhpQ1VCbEZqWnQ1a3pzX3FwaGVHQQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-27T15:43:01+00:00", "published_display": "27 Oct 2025 15:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNZGFMMk8wYVU5aExvLS1RZXJXRVZQSzM4bnhnYy00bE9kUE96NWpwa05oMW5BQW5Fb2FHbmhUejlhOWxXNmFMUnd6aDFmeU9yTVQ1QzBXaFpLekpjbG9nUWJOekhTMnJidEl0Y0UtTGtzZXdjREtRNDFEVXREaDdLazlOYWJYdkVDLURNSzhWT0l6YUZZSFV5c1M0dmkwakdUYTB4U2t1dw?oc=5", "source_name": "Investopedia", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPYkdRdnl1ekhjeXZYY0NmY3U0bE5CaWM1d0tnUVNLU2RiYnJfMnBHdElJc082NU8wQ0JnaktNMVNLZTNSTEdQTmREV1ByekJvMV9fdUVuSmx1TERRV0NIZUs2Wkpodno5VTIyNEdIbDFMemFvUHVDeE0xYmJGeC00bGlXcXVYblhLWnI1X2pkUGl1UGpWR3JhUjNOZjg4ZFFNRWc?oc=5", "source_name": "CNBC", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 56, "sentiment_summary": {"positive": 14, "negative": 8, "neutral": 34, "score": 51, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 21.8, "count": 39}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 23.42, "latest_week": "2026-07-10", "one_week_move": 1.5, "four_week_move": 28.8, "twelve_week_move": 14.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.389465, "market_dynamics_buy_signal": false, "relative_strength": 19.208891, "fair_value_gap": 19.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.449, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.5% over one week, +28.8% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "Investing.com Canada", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "GlobeNewswire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 39}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+1.5% over one week, +28.8% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Dyne Therapeutics (DYN) Inspires Confidence With Its Force Platform"}], "updated_at": "2026-07-16T10:36:30.078993+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}